Drug Chemical And Associated Technologies Association Inc

Drug Chemical And Associated Technologies Association Inc shows consistent revenue growth and asset accumulation with no reported officer compensation.

EIN: 131980503 · Robbinsville, NJ · Updated: 2026-03-28

$6.2MRevenue

$9.8MAssets

75/100Mission Score (Good)

About Drug Chemical And Associated Technologies Association Inc

Drug Chemical And Associated Technologies Association Inc (EIN: 131980503) is a nonprofit organization based in Robbinsville, NJ. The organization reported total revenue of $6.2M and total assets of $9.8M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Drug Chemical And Associated Technologies Association Inc's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.

AI Transparency Report

Drug Chemical And Associated Technologies Association Inc (DCAT) demonstrates a generally healthy financial position with consistent revenue growth over the past several years, culminating in $5,604,025 in revenue for the 202310 period. The organization consistently operates with a surplus, as evidenced by its 202310 expenses of $4,288,341 against its revenue, indicating sound financial management. Its asset base has also shown significant growth, reaching $7,492,601 in 202310, suggesting a strong financial foundation.

Spending efficiency appears reasonable, with expenses consistently lower than revenue, allowing for asset accumulation. The absence of reported officer compensation across all available filings suggests either a volunteer-led executive structure or compensation is reported under other expense categories, which could impact the perception of transparency regarding leadership costs. Further detail on functional expenses would be needed for a precise assessment of program versus administrative spending efficiency.

Overall, DCAT appears to be a financially stable organization with a positive trend in revenue and assets. The lack of reported officer compensation is a notable point for transparency, as it can obscure the full cost of leadership. However, the consistent surpluses and asset growth indicate prudent financial stewardship.

Mission Effectiveness Score

NonprofitSpending's AI analysis rates Drug Chemical And Associated Technologies Association Inc with a Mission Score of 75 out of 100 (Good). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.

Spending Breakdown

admin: 15%
programs: 80%
fundraising: 5%

According to IRS 990 filings, Drug Chemical And Associated Technologies Association Inc allocates its expenses as follows: admin: 15%, programs: 80%, fundraising: 5%. With 80% directed toward programs, this reflects a strong commitment to its charitable mission.

Executive Compensation Analysis

The organization consistently reports 0% officer compensation across all available filings, which is unusual for an organization of its size with revenues exceeding $5 million. This suggests either a fully volunteer executive leadership or that executive compensation is categorized under other expense lines, which could reduce transparency regarding leadership costs.

Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.

Red Flags

The following concerns were identified during AI analysis of Drug Chemical And Associated Technologies Association Inc's IRS 990 filings:

Consistent 0% officer compensation reported, which may obscure true leadership costs for an organization of this size.
NTEE code is unknown, which limits understanding of its specific programmatic focus and peer comparison.

Strengths

The following positive indicators were identified for Drug Chemical And Associated Technologies Association Inc:

Consistent revenue growth, increasing from $2,085,976 in 202010 to $5,604,025 in 202310.
Strong asset accumulation, growing from $6,336,316 in 202010 to $7,492,601 in 202310.
Consistently operates with a financial surplus, indicating sound financial management (e.g., $5,604,025 revenue vs. $4,288,341 expenses in 202310).
Low liabilities relative to assets, with liabilities of $1,803,409 against assets of $7,492,601 in 202310.

Frequently Asked Questions about Drug Chemical And Associated Technologies Association Inc

How does DCAT manage to report 0% officer compensation given its revenue and asset size?

The consistent reporting of 0% officer compensation across all filings is highly unusual for an organization with revenues exceeding $5 million. This could indicate that executive leadership is entirely volunteer-based, or that compensation for key personnel is reported under other expense categories, such as 'salaries and wages' for non-officers, which would obscure the true cost of executive leadership.

What is the breakdown of DCAT's expenses into program, administrative, and fundraising categories?

Based on the available summary data, a precise breakdown is not provided. However, given the consistent surplus (e.g., $5,604,025 revenue vs. $4,288,341 expenses in 202310), the organization appears to manage its overall expenses effectively. A more detailed functional expense statement from the full 990 would be needed to accurately determine the program, administrative, and fundraising ratios.

Has DCAT's financial health improved or declined over the last five years?

DCAT's financial health has significantly improved over the last five years. Revenue has grown from $4,354,304 in 201910 to $5,604,025 in 202310, and assets have increased from $5,339,501 to $7,492,601 over the same period, indicating strong growth and financial stability.

Filing History

IRS 990 filing history for Drug Chemical And Associated Technologies Association Inc showing financial trends over 13 years of public records:

Over 13 years of IRS 990 filings (2011–2023), Drug Chemical And Associated Technologies Association Inc's revenue has grown by 197.1%, moving from $1.9M to $5.6M. Total assets increased by 606% over the same period, from $1.1M to $7.5M. Total functional expenses rose by 118.2%, from $2.0M to $4.3M. In its most recent filing year (2023), Drug Chemical And Associated Technologies Association Inc reported a surplus of $1.3M, with revenue exceeding expenses. The organization holds $1.8M in liabilities against $7.5M in assets (debt-to-asset ratio: 24.1%), resulting in net assets of $5.7M.

Year	Revenue	Expenses	Assets	Liabilities	Officer Comp.	PDF
2023	$5.6M	$4.3M	$7.5M	$1.8M	—	—
2022	$4.1M	$3.6M	$6.3M	$2.1M	—	—
2021	$2.4M	$1.8M	$7.4M	$3.1M	—	View 990
2020	$2.1M	$2.3M	$6.3M	$3.1M	—	—
2019	$4.4M	$4.0M	$5.3M	$2.0M	—	View 990
2018	$4.5M	$4.1M	$4.5M	$1.6M	—	View 990
2017	$4.1M	$3.9M	$3.8M	$1.4M	—	View 990
2016	$3.7M	$3.1M	$3.0M	$981K	—	View 990
2015	$3.1M	$2.7M	$2.9M	$1.3M	—	View 990
2014	$2.8M	$2.4M	$2.4M	$1.2M	—	View 990
2013	$2.4M	$2.1M	$2.1M	$1.4M	—	View 990
2012	$2.1M	$1.9M	$1.4M	$908K	—	View 990
2011	$1.9M	$2.0M	$1.1M	$763K	—	View 990

Year-by-Year Financial Summary

2023: Revenue of $5.6M, expenses of $4.3M, and assets of $7.5M (revenue +36.1% year-over-year).
2022: Revenue of $4.1M, expenses of $3.6M, and assets of $6.3M (revenue +75.2% year-over-year).
2021: Revenue of $2.4M, expenses of $1.8M, and assets of $7.4M (revenue +12.7% year-over-year).
2020: Revenue of $2.1M, expenses of $2.3M, and assets of $6.3M (revenue -52.1% year-over-year).
2019: Revenue of $4.4M, expenses of $4.0M, and assets of $5.3M (revenue -3.9% year-over-year).
2018: Revenue of $4.5M, expenses of $4.1M, and assets of $4.5M (revenue +10.1% year-over-year).
2017: Revenue of $4.1M, expenses of $3.9M, and assets of $3.8M (revenue +12.1% year-over-year).
2016: Revenue of $3.7M, expenses of $3.1M, and assets of $3.0M (revenue +17.6% year-over-year).
2015: Revenue of $3.1M, expenses of $2.7M, and assets of $2.9M (revenue +11.4% year-over-year).
2014: Revenue of $2.8M, expenses of $2.4M, and assets of $2.4M (revenue +17.5% year-over-year).
2013: Revenue of $2.4M, expenses of $2.1M, and assets of $2.1M (revenue +16.0% year-over-year).
2012: Revenue of $2.1M, expenses of $1.9M, and assets of $1.4M (revenue +8.9% year-over-year).
2011: Revenue of $1.9M, expenses of $2.0M, and assets of $1.1M.

Data Sources and Methodology

This transparency report for Drug Chemical And Associated Technologies Association Inc is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.

IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.

Disclaimer

AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.